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Ligation of lymph vessels for the treatment
of recurrent inguinal lymphoceles following
lymphadenectomy
Navid Mohamadpour Toyserkani, Henrik Toft Nielsen, Vivi Bakholdt and Jens Ahm Sørensen*
Abstract
Background: Recurrent lymphocele following groin dissection is generally a self-limiting condition, but in a few
cases, the lymphocele persists and for this, there are not many options. Few reports have proposed the efficacy of
lymph vessel ligation with patent blue as a vessel locator. We have used this technique since 2007 in our very
severe cases and herein present our results.
Methods: The study was a retrospective case series in a university hospital setting. All patients who had this procedure
performed were included from the first procedure performed in 2007 until August 2015, and their data was retrieved
from electronic patient records.
Results: In total, eight patients had this procedure performed for a total of ten inguinal regions. In all regions, leaking
lymph vessels were easily found by the blue color and a median of 3 (range 1–5 vessels) vessels per region were ligated
using titanium clips. For two patients, there was still a need for puncture which lasted 13–37 days postoperatively. For
the remaining patients, there was an immediate stop in lymphocele formation but one patient developed a lymphatic
malformation which after removal resulted in the recurrence of lymphocele and had the procedure performed again
with immediate effect.
Conclusions: Ligation of lymph vessels for the treatment of recurrent inguinal lymphoceles appears to be an appropriate
treatment modality that is both quick and easy to perform with minimum risk, and in most cases, it results in immediate
complete stop in the lymphocele formation.
Background
Inguinal lymphadenectomy is depending on cancer
stage, a standard part of surgical treatment of several
cancer types (squamous cell carcinoma, melanoma, etc).
This treatment is associated with high rates of morbidity
which include wound infection, necrosis of skin flaps,
lymphedema, and also recurrent lymphoceles in the sur-
gical site [1].
Recurrent lymphoceles may be without symptoms but
can also be associated with pain and movement restric-
tion. The occurrence of lymphoceles after inguinal lymph-
adenectomy is very common with an incidence of 11 % in
melanoma patients [2], and similar numbers are produced
for other cancer types.
Many different approaches have been tried to prevent
or minimize lymphocele formation with inconsistent re-
sults. In general, this condition is self-limiting, but in
some cases, there is no end in sight for the recurrence
of the lymphocele. In the last decades, a few case reports
and small series have suggested that using patent blue to
identify leaking lymph vessels could be the solution to
this problem [3–5].
Since 2008, we have used this technique in cases where
the lymphocele formation was either unmanageable or
where there was no end in sight for the lymphocele for-
mation. We present our results with the technique.
Methods
This study was conducted as a retrospective study in a
tertiary hospital department setting. All patients that
had previously had lymph vessel ligature were identified
through our electronic patient records using relevant
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surgical procedure codes. In addition, operating theater
lists were checked manually to ensure complete inclu-
sion. The inclusion dates ranged from 2004 (January) to
2015(August). Case files were read, and demographic,
procedure, and outcome-related data was gathered.
All patients were treated in compliance with the Helsinki
Declaration. Patients included in this retrospective study
were not treated as part of a clinical study. Ethical approval
from an ethics committee was not needed for this retro-
spective study.
The surgical procedure began in all cases with the injec-
tion of patent blue at the level of the ankle with the injec-
tion of 0.5 ml. The leg was then elevated and massaged.
The surgical site in the inguinal region was then explored,
and within 5 min of injection, blue lymph vessels and leaks
were noted. See Figs. 1, 2, and 3 for intraoperative photo-
graphs. All these were ligated with titanium clips. The
wound was then either closed in layers with or without
drainage (operator dependent) or closed with vacuum-
assisted closure (VAC) because of contamination of the
surgical site. Drains were removed when there was a pro-
duction of less than 50 ml within 24 h.
Results
In total, lymph vessel ligation was performed ten times in
the inguinal region in a total of eight patients as one case
was a bilateral case and one case was treated twice. Four
were male, and the median age at surgery was 70 years
(range 44–78 years). The median number of days from
original surgery to time of lymph vessel ligature was
32 days (range 15–144). The patients were all treated in
the periods 2007 and 2015, and the minimum follow-up
time was 4 months. The patient characteristics are sum-
marized in Table 1.
Preoperatively, a median of three blue leaking lymph
vessels were found and ligated (range 1–5 vessels). In six
cases, the wound was closed routinely in layers, and in
the remaining two cases, VAC was used due to the
contamination of the surgical site. In cases with direct
suture, drains were placed based on the preference of
the surgeon. Drains were removed when the daily pro-
duction was less than 50 ml.
For two patients including the bilateral case, there was
a need for postoperative fluid drainage which ranged
from 13 to 37 days to the last puncture date. Another
patient with an immediate good response to vessel
ligation was suspected of having recurrence of melan-
oma 3 months after vessel ligation. PET-CT revealed
that the inguinal bulge was a lymphatic malformation
which was removed surgically. Lymphocele formation
followed the removal of the lymphatic malformation
and was treated conservatively for 5 months without ef-
fect. The lymph vessel ligation procedure was repeated
with an immediate positive response again. In the
remaining five patients, there was a complete immedi-
ate response without recurrence. Once the lymphocele
formation had ceased, no one had recurrence in the
follow-up period.
No other postoperative complications were noted in
any cases.
Fig. 1 Intraoperative photograph showing the cavity before patent
blue injection
Fig. 2 Intraoperative photograph showing injection of patent blue
at the level of the ankle
Fig. 3 Intraoperative photograph showing the blue leaking lymph
vessel in the cavity five minutes after injection of patent blue
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Discussion
In total, we have performed this procedure in eight pa-
tients with a total of ten inguinal regions. In two patients
(three regions), further puncture of the surgical site was
necessary up to about 1 month after surgery. In these
two patients, the mean duration of the lymphocele was
just less than 1 month and one can wonder if these cases
would have regressed spontaneously in the same time
frame without surgery. In the remaining cases, there was
no need for further puncture after the procedure. Some
of the effect attributed to this procedure might also be
contributed by the postoperative immobilization, which
is often recommended to minimize fluid accumulation.
Previous literature regarding ligature of lymph vessels is
very sparse, but previous case reports and series all show
improvement postoperatively in all cases [3–5]. In our
series, we show that the need for puncture does not neces-
sarily end right after surgery and one can expect that in
some cases, there will be a need for further drainage in
the first few weeks postoperatively. The same case reports
have injected the Patent Blue V in the food distally in the
interdigital spaces; however, we have opted to inject the
dye at the level of the ankle and in all cases, we could
identify blue lymph vessels in the inguinal area.
We did not experience any postoperative complications
with this procedure besides one patient that developed a
lymphatic malformation. This was surgically removed, but
resulted in the recurrence of lymphocele which was then
treated again with immediate effect. It is a very easy, sim-
ple, and quick procedure that has the potential to benefit
patients where other options are sparse. In six out of eight
patients, this procedure led to an immediate stop to the
lymphocele formation.
It is interesting to note that the patients that did not
have an immediate stop of their lymphocele had drains
placed which were removed within a few days after sur-
gery due to low production in the drains. Patients without
drains or with VAC closure all had immediate effect of the
procedure. The patient material however is very small,
and nothing can be concluded on whether to use drains
or not.
One could also hypothesize that this procedure could
be used while performing the actual lymphadenectomy
to minimize the risk of later lymphocele formation. This
is however just a speculation and would need to be ex-
amined in a properly designed clinical trial.
Conclusions
Ligation of lymph vessels can be an effective treatment
modality for recurrent inguinal lymphoceles following
inguinal lymphadenectomy where the lymphocele for-
mation is not decreasing or the fluid accumulation is
just too dramatic to warrant a conservative approach.
The treatment is quick and easy to perform but should
be reserved for the unmanageable cases to avoid over-
treating patients as the condition is usually self-limiting.
In the severe cases, lymph vessel ligation can be recom-
mended but the evidence for this treatment is still only
on a case series basis.
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1 Female 44 Melanoma 32 Left 2 Drain 4 Noa
2 Female 78 Lymphoma 84 Left 4 None – No
3 Female 62 Melanoma 32 Right 5 Drain 21 No
4 Male 60 Penile SCC 39 Left 3 VAC 17 No
5 Male 70 Melanoma 26 Bilateral 3/2 Drain 1/5 Yes/yes
6 Female 70 Melanoma 27 Right 2 Drain 3 Yes
7 Male 76 Melanoma 15 Right 3 VAC 5 No
8 Female 72 Ovarian cancer 144 Right 1 None – No
VAC vacuum-assisted closure
aPostoperatively developed lymphatic malformation, which was surgically removed. After this procedure, lymphocele developed again which in the end was
treated with a renewed vessel ligation procedure
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